Search for: "US v. James Poole" Results 81 - 100 of 205
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
10 Dec 2009, 6:09 am by James Morphy, Sullivan & Cromwell LLP,
Editor's Note: James Morphy is a partner at Sullivan & Cromwell LLP specializing in mergers & acquisitions and corporate governance. [read post]
13 Jun 2008, 3:40 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: ECJ rules trade mark holders cannot stop honest comparative advertising: O2 Holdings Limited and O2 (UK) Limited v Hutchinson 3G UK Limited: (Out-Law), (Catch Us If You Can!!!) [read post]
27 Dec 2017, 6:41 pm by Jason Rantanen
Top-down approaches were used by the UK court in in Unwired Planet and by the Japanese IP High Court in Apple Japan v. [read post]
11 Oct 2018, 2:30 pm by Dale Carpenter
Thus, in the classic case of James v Eastleigh Borough Council [1990] 2 AC 751, the criterion used for allowing free entry to the council's swimming pool was not sex but statutory retirement age. [read post]
10 Oct 2018, 2:30 pm by Dale Carpenter
Thus, in the classic case of James v Eastleigh Borough Council [1990] 2 AC 751, the criterion used for allowing free entry to the council's swimming pool was not sex but statutory retirement age. [read post]
28 Mar 2017, 9:05 am by Lyle Denniston
  Since it issued the famous decision 15 years ago in Atkins v. [read post]
13 Jul 2014, 11:00 pm by Kingsley Egbuonu
The importance of the claims in patent infringement proceedings has also been reaffirmed by the Nigerian case of James Oitomen Agboronto v. [read post]
4 Jul 2016, 3:41 pm by James E. Novak, P.L.L.C.
For pool parties, cook-outs, and other outdoor activities, make sure guests have access to a cool and shaded location. [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at… [read post]